Solstice Neurosciences, Inc.

New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia

    Malvern, Pennsylvania (ots/PRNewswire) -

    - Solstice Neurosciences, Inc. Launches a Self-Guided Lesson as Prep for In-Person Workshops

    In recognition that physician comfort and knowledge with techniques around botulinum toxin injections lead to the best results for patients with cervical dystonia (CD), Solstice Neurosciences, Inc. (Solstice) has created MYOBLOC(TM) University, an online, self-study resource that incorporates new learning technology. The course integrates multi-dimensional, life-like animation throughout the content -- with anatomy based on real patients with CD and actual injection technique demonstrations with Myobloc(R) (Botulinum Toxin Type B) Injectable Solution. The course can be accessed at www.myoblocuniversity.com.

    "MYOBLOC(TM) University is for busy physician specialists who want to expand the scope of treatment options for their patients with cervical dystonia, and for those seeking a comprehensive review of the condition and the role of botulinum toxin type B," said Eric J. Pappert, MD, assistant professor of neurology and director of the Parkinson's Disease and Movement Disorders Program at the University of Texas Health Science Center in San Antonio, Texas and Vice President, Medical & Scientific Affairs of Solstice. Dr. Pappert led the development of MYOBLOC(TM) University.

    CD is often a disabling and painful movement disorder that requires life-long management. Also known as spasmodic torticollis, it is a condition that primarily affects the cervical area of the neck. While the exact cause of CD is unknown, scientists believe the problem originates in the basal ganglia area of the brain that is instrumental in movement. The treatment goal is to lessen symptoms of spasms, pain and impaired posture, and to improve functionality.

    "A broad range of treatment options are often needed to address the symptoms of cervical dystonia. The botulinum toxins are considered the primary and most effective form of treatment, which makes it critically important for physicians to be experienced with both forms of botulinum toxin available here in the U.S.," noted Dr. Pappert.

@@start.t1@@      The multi-media content covered in MYOBLOC(TM) University includes:
      -- Detailed overview of the clinical presentation and diagnosis of
          CD -- with video depictions demonstrating abnormal movements and which
          Muscle are involved
      -- Review of currently available treatments -- oral medications, surgical
          options, injections with botulinum toxin, and complementary therapies
      -- Fundamentals for dosing and muscle injection techniques when using
          MYOBLOC to reduce the severity of abnormal head position and neck pain
          associated with CD
      -- Patient case studies that illustrate the challenges and potential
          solutions in managing CD patients
      -- A post-test for participants to gauge their understanding of the
          materials presented@@end@@

    Upon completing the online lesson, physicians can request in-person training with MYOBLOC, which is available through Solstice in a variety of venues. The company's overall goal is to support physicians who care for CD patients -- ranging from neurologists to physiatrists to anesthesiologists and pain management physicians.

    MYOBLOC(TM) University does not offer continuing medical education credits.

    About MYOBLOC

    Myobloc(R) (Botulinum Toxin Type B) Injectable Solution is indicated for the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.

    Before administering MYOBLOC, physicians should consult the full Prescribing Information.

    The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. These adverse events are generally mild to moderate, transient, self-resolving, and more common with higher doses.

    For full Prescribing Information, please visit www.myobloc.com.

    About Solstice Neurosciences, Inc.

    Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, MYOBLOC, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold in the EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit www.solsticeneuro.com

    Myobloc(R) and NeuroBloc(R) are registered trademarks of Solstice Neurosciences, Inc.

    Editor's Note: for access to current course offerings, users must register on website; users can access site regardless of medical credentials.

      Web site: http://www.myoblocuniversity.com
                      http://www.solsticeneuro.com

ots Originaltext: Solstice Neurosciences, Inc.
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
Erin Evans of Cooney/Waters Group, +1-212-886-2260,
eevans@cooneywaters.com, for Solstice Neurosciences, Inc.



Weitere Meldungen: Solstice Neurosciences, Inc.

Das könnte Sie auch interessieren: